Canadian Cancer Trials Group Bulletins


LACE-Bio-II Awarded NIH Grant

The Canadian Cancer Trials Group is very pleased to announce that Dr. Lesley Seymour and colleagues -- Drs Keyue Ding, Ming Tsao, Frances Shepherd, Igor Jurisica, John McPherson, Stephen Graziano, Robert Kratzke, Ramaswamy Govindan, Richard Wilson, Jean-Pierre Pignon, Jean-Charles Soria, Jean-Yves Douillard, Elisabeth Brambilla, Gwenael LeTeuff and Stefan Michiels -- have been awarded a $2.3M R01 grant from the US National Institutes of Health to identify, validate and implement prognostic / predictive biomarkers for adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC).

These investigators from the four pivotal adjuvant chemotherapy NSCLC trials (IALT, CALGB 9633, JBR.10, ANITA) formed the Lung Adjuvant Cisplatin Evaluation (LACE)-Bio-I consortium to conduct cross-validation/pooled meta-analyses of biomarkers that each group had identified on collected formalin fixed tumour (FFPE) to confirm their robustness/utility in a larger dataset. LACE-Bio-I focused predominantly on immunohistochemical methods (IHC) and single gene analyses.

The LACE-Bio-II project builds on the successful LACE-Bio-I collaboration and will use multiple cutting edge technologies to conduct validation studies of the prognostic and predictive gene expression signature identified in JBR10, as well as explore novel genomic predictive and prognostic markers.

Congratulations to all!!!